ClinicalTrials.Veeva

Menu
D

D&H National Research Centers | Miami, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Cenerimod
Dexlansoprazole
Tc 99m
Lanifibranor
Camoteskimab
Pomotrelvir
EDP-235
SEL-212
PBI-0451
Dupilumab

Parent organization

This site is a part of D&H National Research Centers

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 24 total trials

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: IVA337

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematous in adult patients with moderate to sever...

Enrolling
Lupus Erythematosus, Systemic
Drug: Cenerimod
Drug: Placebo

The main aims of the study are to see the* side effects of Dexlansoprazole treatment* effectiveness of Dexlansoprazole treatment in children having s...

Enrolling
Gastroesophageal Reflux Disease (GERD)
Drug: Dexlansoprazole

The main aims of the study are to check the* side effects and effectiveness of Dexlansoprazole in healing erosive esophagitis (EE)* side effects and...

Enrolling
Erosive Esophagitis
Drug: Dexlansoprazole
Locations recently updated

This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety...

Enrolling
Atopic Dermatitis
Eczema Atopic Dermatitis
Drug: Placebo
Drug: Camoteskimab

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Dupilumab

Study of EDP-235 in Non-hospitalized Adults with Mild or Moderate COVID-19.

Enrolling
COVID-19
Drug: Placebo
Drug: EDP-235

The study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus peglot...

Enrolling
Gout
Drug: Methotrexate
Biological: Pegloticase

This study assesses the efficacy, safety, and pharmacokinetics of multiple-dose oral administration of daridorexant in pediatric subjects aged 10 to...

Enrolling
Insomnia
Drug: Daridorexant 10 mg
Drug: Daridorexant 25 mg

This is a phase 2 double-blind, randomized study of PBI-0451(Pomotrelvir) in nonhospitalized symptomatic adults with COVID-19. PBI-0451(Pomotrelvir)...

Active, not recruiting
COVID-19
Drug: PBI-0451 (Pomotrelvir)
Drug: Placebo

The study will evaluate the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273.214 severe acute respiratory syndrome coronavirus 2...

Enrolling
SARS-CoV-2
Other: Placebo
Biological: mRNA-1273.214

This study will confirm the ability of Tc 99m tilmanocept imaging to predict clinical response in individuals with RA who are beginning anti-TNFα the...

Active, not recruiting
Rheumatoid Arthritis
Drug: TC99m-tilmanocept

Trial sponsors

Idorsia Pharmaceuticals logo
Amgen logo
Takeda logo
Thermo Fisher Scientific logo
AbbVie logo
Abbott logo
A
Enanta Pharmaceuticals logo
E
Gilead Sciences logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems